Search
Selected Filter
Displaying 1–10 of 252 research results
-
ReNeuron Not Continuing Clinical Development of Cell-Based Therapy for RP
Company seeks to out-license its retinal progenitor therapy to a partner
-
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
-
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
-
Age-Related Macular Degeneration Research Advances
Recent developments in research on age-related macular degeneration.
-
Retinitis Pigmentosa Research Advances
Recent developments in research on retinitis pigmintosa.
-
Usher Syndrome Research Advances
Recent developments in research on Usher Syndrome.
-
Stargardt Disease Research Advances
Recent developments in research on Stargardt disease
-
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
.png)
.png)
